UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): March 10, 2017
 
 
BIONIK LABORATORIES CORP.
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
 
000-54717
 
27-1340346
(State or Other Jurisdiction of Incorporation or Organization)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
483 Bay Street, N105
Toronto, ON
 
 
M5G 2C9
(Address of Principal Executive Offices)
 
 
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (416) 640-7887
 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Item 7.01
Regulation FD Disclosure
 
On March 10, 2016, Bionik Laboratories Corp. (the “Registrant”) issued a press release regarding that it has been made aware of and requested by the OTC Markets Group, Inc. to comment on recent trading and promotional activity concerning its common stock.
 
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
 
Item 9.01
Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit No.                                Description
 
99.1                      Press Release
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date:  March 13, 2017
 
 
BIONIK LABORATORIES CORP.
 
 
 
 
 
By:
/s/ Leslie Markow
 
Name: 
Leslie Markow
 
Title: 
Chief Financial Officer